Enanta Pharmaceuticals, Inc. (ENTA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1153659,
    "name": "Enanta Pharmaceuticals, Inc.",
    "stock_name": "Enanta Pharmaceuticals, Inc.",
    "full_name": "Enanta Pharmaceuticals, Inc.",
    "name_url": "stocks-analysis/enanta-pharmaceuticals-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "14.09",
    "chg": 0.13,
    "chgp": "0.93%",
    "dir": 1,
    "prev_price": "13.96",
    "mcapval": "190.48",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US29251M1062",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "492.11 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/enanta-pharmaceuticals-inc-1153659-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Enanta Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-enanta-pharmaceuticals-inc-technically-bullish-or-bearish-3546585",
        "imagepath": "",
        "date": "2025-09-20 19:36:17",
        "description": "As of 10 September 2025, the technical trend for Enanta Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages also indicate a mildly bullish stance. However, the Bollinger Bands show a mixed signal with a mildly bullish weekly outlook and a bearish monthly outlook. The KST is bullish on a weekly basis but bearish monthly, and Dow Theory presents a mildly bearish weekly view alongside a mildly bullish monthly perspective. The OBV is mildly bearish weekly but mildly bullish monthly.\n\nIn terms of performance, Enanta Pharmaceuticals has underperformed relative to the S&P 500 over the past week and month, with returns of -9.47% and -4.04% respectively, while the S&P 500 gained 1.05% and 2.33%. However, year-to-date, the stock has outperformed the benchmark with a return of 36.35% compared to the S&P 500's ..."
      },
      {
        "title": "Is Enanta Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-enanta-pharmaceuticals-inc-overvalued-or-undervalued-3543128",
        "imagepath": "",
        "date": "2025-09-20 18:11:26",
        "description": "As of 25 November 2020, the valuation grade for Enanta Pharmaceuticals, Inc. moved from expensive to risky, indicating a shift in perception regarding its valuation. The company appears to be overvalued based on its financial metrics, particularly given its negative P/E ratio and poor returns on capital, with a Price to Book Value of 1.71, EV to Sales of 1.95, and a troubling ROCE of -170.84%. \n\nIn comparison to peers, Enanta's EV to EBITDA stands at -1.27, while Y-mAbs Therapeutics, Inc. has a significantly higher EV to EBITDA of -12.49, and scPharmaceuticals, Inc. at -4.64, highlighting that Enanta is underperforming relative to its industry. The stock's performance has been lackluster, with a 1Y return of -31.17% compared to the S&P 500's 17.14%, reinforcing the notion that the stock is overvalued in the current market context...."
      }
    ],
    "total": 7,
    "sid": "1153659",
    "stock_news_url": "https://www.marketsmojo.com/news/enanta-pharmaceuticals-inc-1153659"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Enanta Pharmaceuticals, Inc. technically bullish or bearish?

2025-09-20 19:36:17

As of 10 September 2025, the technical trend for Enanta Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages also indicate a mildly bullish stance. However, the Bollinger Bands show a mixed signal with a mildly bullish weekly outlook and a bearish monthly outlook. The KST is bullish on a weekly basis but bearish monthly, and Dow Theory presents a mildly bearish weekly view alongside a mildly bullish monthly perspective. The OBV is mildly bearish weekly but mildly bullish monthly. In terms of performance, Enanta Pharmaceuticals has underperformed relative to the S&P 500 over the past week and month, with returns of -9.47% and -4.04% respectively, while the S&P 500 gained 1.05% and 2.33%. However, year-to-date, the stock has outperformed the benchmark with a return of 36.35% compared to the S&P 500's ...

Is Enanta Pharmaceuticals, Inc. overvalued or undervalued?

2025-09-20 18:11:26

As of 25 November 2020, the valuation grade for Enanta Pharmaceuticals, Inc. moved from expensive to risky, indicating a shift in perception regarding its valuation. The company appears to be overvalued based on its financial metrics, particularly given its negative P/E ratio and poor returns on capital, with a Price to Book Value of 1.71, EV to Sales of 1.95, and a troubling ROCE of -170.84%. In comparison to peers, Enanta's EV to EBITDA stands at -1.27, while Y-mAbs Therapeutics, Inc. has a significantly higher EV to EBITDA of -12.49, and scPharmaceuticals, Inc. at -4.64, highlighting that Enanta is underperforming relative to its industry. The stock's performance has been lackluster, with a 1Y return of -31.17% compared to the S&P 500's 17.14%, reinforcing the notion that the stock is overvalued in the current market context....

View All News